{"url_path":"/sec/inkt/10-q/2026/item-4","section_key":"item-4","section_title":"Item 4 Controls and Procedures.","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-15","source_url":"https://www.sec.gov/Archives/edgar/data/1840229/0001193125-26-226804-index.html","accession_number":"0001193125-26-226804","cik":"0001840229","ticker":"INKT","issuer_name":"MiNK Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1840229/0001193125-26-226804-index.html","primary_entity_key":"0001840229","primary_entity_name":"MiNK Therapeutics, Inc."},"word_count":267,"has_tables":true,"body_markdown":"Item 4. Controls and Procedures.\n\nEvaluation of Disclosure Controls and Procedures\n\nWe maintain disclosure controls and procedures (as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosures. In designing and evaluating our disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives and management necessarily applies its judgment in evaluating the benefits of possible controls and procedures relative to their costs.\n\nOur management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures as of March 31, 2026. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective as of March 31, 2026 at the reasonable assurance level.\n\nChanges in Internal Control Over Financial Reporting\n\nThere was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that occurred during the three months ended March 31, 2026 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.\n\n18\n\n \n\nPART II—OTHER INFORMATION"}